Application of PAX1/JAM3 Dual-Gene Methylation in Cervical Cancer Screening and Treatment
LIU Qian
YANG Fan
XU Ran
WANG Xin-li
Abstract：Cervical cancer ranks second in the incidence of female malignant tumors in China and is one of the main causes of female cancer-related deaths.Moreover,the overall incidence showed an upward trend.Currently,the thin-prep cytology test(TCT)and high-risk human papilloma virus(HR-HPV)DNA testing are the main screening methods for cervical cancer.However,both have limitations.The TCT results have poor reproducibility and low sensitivity,while the HR-HPV DNA test has low specificity,which may lead to over-diagnosis and over-treatment.Therefore,a more accurate screening program is urgently needed.With the rapid development of DNA methylation detection technology,multiple gene methylations have been used in cervical cancer screening.Among them,the methylation of paired box gene 1(PAX1)/junctional adhesion molecule 3(JAM3)dual-gene has attracted much attention.Some studies have reported that it is related to the migration and invasion of cervical cancer cells.Although the current related research is not yet perfect,the PA X1/JAM3 dual-gene methylation has great potential in the field of cervical cancer screening and treatment.The combined application of PAX1/JAM3 dual-gene methylation can help optimize the cervical cancer screening strategy and improve the accuracy of clinical triage.This review summarizes the application of PAXl/JAM3 dual-gene methylation in cervical cancer screening and treatment,aiming to provide a theoretical basis for the precise implementation and hierarchical management of cervical cancer screening.
Keywords：Cervical intraepithelial neoplasiaUterine cervical neoplasmsDNA methylationPaired box gene 1Junctional adhesion molecule 3
Publication Date：2025-12-15
Online Publishing Date：2026-01-13(First online date of this platform, not the publication date of the document)
Pages：6( 702-707 )